Friedrich A. Grasser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Friedrich A. Grasser has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Elisabeth Kremmer
3 shared publicationsNikolaus Mueller-Lantzsch
Institut für Mikrobiologie und Hygiene, Abteilung Virologie, Haus 47, Universitätskliniken, D-66421 Homburg/Saar, Germany
3 shared publicationsNicole Fischer
Institut für Mikrobiologie und Hygiene, Abteilung Virologie, Universitätskliniken, Homburg/Saar, Germany
2 shared publicationsAlexander Krebs
1 shared publication- Bernd F. M. Romeike
Department of the Dean of Studies in Medical Didactics, University Medical Centre Rostock, Rostock, Germany
1 shared publication Christian Sauder
Institut für medizinische Mikrobiologie und Hygiene der Universitätskliniken des Saarlandes
1 shared publication
Latest Publications
- 1 December 2001
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 2 (4) , 349-360
dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
With the exception of brain, most human tissues analysed contain dUTPase protein detectable by immunohistochemistry. Non-dividing tissues like untreated peripheral blood lymphocytes (PBLs) contain basal levels of cytoplasmic dUTPase and express additional, nuclear dUTPase upon mitogenic stimulation. Normal, proliferating tissues like intestinal mucosa or germinal centres within tonsils contain cytoplasmic as well as nuclear dUTPase in accordance with a proposed role for dUTPase during cell division. Notably, no dUTPase is detectable during mitosis. The failure to stain dUTPase in normal brain tissue by immunohistochemistry while mRNA is readily detectable by Northern blotting cannot be explained at this moment. Epithelial tumours, such as adenocarcinoma of the lung, breast, colon, vulva or nasopharynx contain cells which are either positive for both or only one of the subcellular forms of the dUTPase and show variable numbers of dUTPase-positive cells. High levels of dUTPase correlate with a poor p rognosis regarding the progression of colorectal carcinoma. Of the intracranial tumours tested, neuroepithelial tumours show almost exclusively nuclear expression whereas meningiomas of higher grades of malignancy (WHO grade II and III) also contain cells with additional cytoplasmic dUTPase. The dUTPase is detectable in other malignancies including tumours derived from lymphatic tissues like Burkitts lymphoma or non-Hodgkins-lymphoma. The downregulation of dUTPase protein during apoptosis or the inhibition of dUTPase during nerve cell development in Drosophila melanogaster suggests a possible role of the enzyme during apoptosis. In line with these observations, inhibition of dUTPase by antisense in p53-deficient tumour cells hints at a possible route of treatment of p53-deficient tumours which are otherwise resistant to therapies like irradiation. The expression of the enzyme in normal tissues indicates that sublethal levels of dUTPase inhibitors may also exert an unwanted mutagenic effect.
- 1 December 2001
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 2 (4) , 349-360
dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
With the exception of brain, most human tissues analysed contain dUTPase protein detectable by immunohistochemistry. Non-dividing tissues like untreated peripheral blood lymphocytes (PBLs) contain basal levels of cytoplasmic dUTPase and express additional, nuclear dUTPase upon mitogenic stimulation. Normal, proliferating tissues like intestinal mucosa or germinal centres within tonsils contain cytoplasmic as well as nuclear dUTPase in accordance with a proposed role for dUTPase during cell division. Notably, no dUTPase is detectable during mitosis. The failure to stain dUTPase in normal brain tissue by immunohistochemistry while mRNA is readily detectable by Northern blotting cannot be explained at this moment. Epithelial tumours, such as adenocarcinoma of the lung, breast, colon, vulva or nasopharynx contain cells which are either positive for both or only one of the subcellular forms of the dUTPase and show variable numbers of dUTPase-positive cells. High levels of dUTPase correlate with a poor p rognosis regarding the progression of colorectal carcinoma. Of the intracranial tumours tested, neuroepithelial tumours show almost exclusively nuclear expression whereas meningiomas of higher grades of malignancy (WHO grade II and III) also contain cells with additional cytoplasmic dUTPase. The dUTPase is detectable in other malignancies including tumours derived from lymphatic tissues like Burkitts lymphoma or non-Hodgkins-lymphoma. The downregulation of dUTPase protein during apoptosis or the inhibition of dUTPase during nerve cell development in Drosophila melanogaster suggests a possible role of the enzyme during apoptosis. In line with these observations, inhibition of dUTPase by antisense in p53-deficient tumour cells hints at a possible route of treatment of p53-deficient tumours which are otherwise resistant to therapies like irradiation. The expression of the enzyme in normal tissues indicates that sublethal levels of dUTPase inhibitors may also exert an unwanted mutagenic effect.
- 26 March 1999
- Published by Wiley in FEBS Letters
- Vol. 447 (2-3) , 311-314
A potential NES of the Epstein‐Barr virus nuclear antigen 1 (EBNA1) does not confer shuttling
The Epstein‐Barr virus nuclear antigen 1 (EBNA1) is a multifunctional protein involved in the replication and maintenance of the viral episome. We identified a potential Rev‐like nuclear export signal (NES) which, however, does not confer the export of EBNA1. In the yeast two‐hybrid system EBNA1 does not bind to the nuclear exporter Crm1p. In spite of the RNA‐binding ability of EBNA1 and its structural homologies to RNA binding proteins like hnRNP U and/or A1, EBNA1 does not shuttle to the cytoplasm in heterokaryon analysis. We propose the function of the RNA binding of EBNA1 in retaining RNAs to the nucleus.
- 26 March 1999
- Published by Wiley in FEBS Letters
- Vol. 447 (2-3) , 311-314
A potential NES of the Epstein‐Barr virus nuclear antigen 1 (EBNA1) does not confer shuttling
The Epstein‐Barr virus nuclear antigen 1 (EBNA1) is a multifunctional protein involved in the replication and maintenance of the viral episome. We identified a potential Rev‐like nuclear export signal (NES) which, however, does not confer the export of EBNA1. In the yeast two‐hybrid system EBNA1 does not bind to the nuclear exporter Crm1p. In spite of the RNA‐binding ability of EBNA1 and its structural homologies to RNA binding proteins like hnRNP U and/or A1, EBNA1 does not shuttle to the cytoplasm in heterokaryon analysis. We propose the function of the RNA binding of EBNA1 in retaining RNAs to the nucleus.
- Open Access
- 1 February 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (7) , 3999-4005
Epstein-Barr Virus Nuclear Antigen 1 Forms a Complex with the Nuclear Transporter Karyopherin α2
- 1 February 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (7) , 3999-4005
Open AccessEpstein-Barr Virus Nuclear Antigen 1 Forms a Complex with the Nuclear Transporter Karyopherin α2
- 1 May 1996
- Published by Microbiology Society in Journal of General Virology
- Vol. 77 (5) , 991-996
Mutational analysis of the Epstein--Barr virus nuclear antigen 2 by far-Western blotting and DNA-binding studies
We have previously shown by far-Western blotting that the Epstein—Barr virus nuclear antigen 2 (EBNA-2) both binds to a cellular protein of 130 kDa and histone H1, with the complex between EBNA-2 and p130 being tighter than between EBNA-2 and histone H1. Here we demonstrate that the N terminus of EBNA-2, which was previously shown to be necessary for transformation of B lymphocytes by EBNA-2, is essential for binding to p130. We further show data indicating that the binding of EBNA-2 to histone H1 appears not to be mediated exclusively via the basic Arg-Gly rich region in the C-terminal part of EBNA-2. With a MAb directed against the Trp-Trp322-Pro (WWP) motif of EBNA-2, which is known to be essential for the interaction of EBNA-2 with the cellular factor RBPJκ/CBF1, we could inhibit the DNA binding of EBNA-2, providing further evidence that this region of EBNA-2 forms direct contact with RBPJκ/CBF1.
- 1 May 1996
- Published by Microbiology Society in Journal of General Virology
- Vol. 77 (5) , 991-996
Mutational analysis of the Epstein--Barr virus nuclear antigen 2 by far-Western blotting and DNA-binding studies
We have previously shown by far-Western blotting that the Epstein—Barr virus nuclear antigen 2 (EBNA-2) both binds to a cellular protein of 130 kDa and histone H1, with the complex between EBNA-2 and p130 being tighter than between EBNA-2 and histone H1. Here we demonstrate that the N terminus of EBNA-2, which was previously shown to be necessary for transformation of B lymphocytes by EBNA-2, is essential for binding to p130. We further show data indicating that the binding of EBNA-2 to histone H1 appears not to be mediated exclusively via the basic Arg-Gly rich region in the C-terminal part of EBNA-2. With a MAb directed against the Trp-Trp322-Pro (WWP) motif of EBNA-2, which is known to be essential for the interaction of EBNA-2 with the cellular factor RBPJκ/CBF1, we could inhibit the DNA binding of EBNA-2, providing further evidence that this region of EBNA-2 forms direct contact with RBPJκ/CBF1.